Ravulizumab
ALXN1210-aHUS-311
Phase 3 mab completed
Quick answer
Ravulizumab for Atypical Hemolytic Uremic Syndrome (aHUS) is a Phase 3 program (mab) at Alexion Europe SAS with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Alexion Europe SAS
- Indication
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Phase
- Phase 3
- Modality
- mab
- Status
- completed